triheptanoin
triheptanoin: 5 clinical trials tracked.
triheptanoin evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about triheptanoin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (5)
Expanded Access to Triheptanoin
A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Primary endpoint: Number of participants with treatment related adverse events as assessed by CTCAE v5.0
A Phase II, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Primary endpoint: Number of participants with treatment related adverse events as assessed by CTCAE v5.0
An Open Label, Exploratory, Proof-of Concept Study of Triheptanoin as Treatment for Patients With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Primary endpoint: Number of participants who report side-effects related to gastrointestinal (GI) distress
A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared With Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Primary endpoint: Annualized Event Rate of Major Clinical Events (MCEs)